Collagen injection before fertility-sparing therapy for early endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether an injection of type III collagen into the uterus before standard progestin therapy can help preserve fertility in women with very early endometrial cancer or atypical hyperplasia. It is designed for women who want to keep the option of having children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of endometrial cancer called endometrioid adenocarcinoma (grade 1 or 2) or atypical endometrial hyperplasia.
- If you have cancer, it must be at a very early stage, confined to the inner lining of the uterus or with only shallow invasion (less than half the thickness of the uterine muscle).
- You are 45 years old or younger.
- You want to preserve your fertility and are willing to sign a consent form.
- You do not have serious medical conditions like severe liver or kidney problems, and you have no reasons that would prevent you from using progestin therapy or becoming pregnant.
- Cancer has not spread to other parts of your body, and you have no active genital infections or allergies to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial studies whether removing an early, hormone-responsive uterine growth using a procedure through the cervix can keep fertility possible. It is for people under 40 with a specific low-risk uterine biopsy and MRI findings who have already tried hormone treatment.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
Hear when a new Atypical Endometrial Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.